Cargando…

Omicron Variant Escapes Therapeutic Monoclonal Antibodies (mAbs) Including Recently Released Evusheld(®), Contrary to 8 Prior Main Variant of Concern (VOC)

Detalles Bibliográficos
Autores principales:	Boschi, Céline, Colson, Philippe, Bancod, Audrey, Moal, Valérie, La Scola, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402686/ https://www.ncbi.nlm.nih.gov/pubmed/35171987 http://dx.doi.org/10.1093/cid/ciac143

Ejemplares similares

Protection from successive Omicron variants with SARS-CoV-2 vaccine and monoclonal antibodies in kidney transplant recipients
por: Moal, Valérie, et al.
Publicado: (2023)

The paradigm of immune escape by SARS-CoV-2 variants and strategies for repositioning subverted mAbs against escaped VOCs
por: Shah, Masaud, et al.
Publicado: (2022)

Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron
por: Hao, Linhui, et al.
Publicado: (2023)

Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant
por: Benotmane, Ilies, et al.
Publicado: (2022)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
por: Chen, Benjamin, et al.
Publicado: (2023)

High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2
por: Jaafar, Rita, et al.
Publicado: (2021)

Rational strategies for enhancing mAb binding to SARS-CoV-2 variants through CDR diversification and antibody-escape prediction
por: Shah, Masaud, et al.
Publicado: (2023)

Impact of mAb-induced A475V substitution on viral fitness and antibody neutralization of SARS-CoV-2 omicron variants in the presence of monoclonal antibodies and human convalescent sera
por: Viriyakitkosol, Ratchanont, et al.
Publicado: (2023)

The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies
por: Focosi, Daniele, et al.
Publicado: (2022)

Omicron variant evolution on vaccines and monoclonal antibodies
por: Sabbatucci, Michela, et al.
Publicado: (2023)

Omicron: the highly mutational COVID-19 variant with immune escape
por: Khajotia, Rumi
Publicado: (2022)

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab
por: Passariello, Margherita, et al.
Publicado: (2022)

Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB
por: Manso, Taciana, et al.
Publicado: (2023)

Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications
por: Haverick, Mark, et al.
Publicado: (2014)

SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects
por: Boschi, Celine, et al.
Publicado: (2022)

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
por: Lindorfer, Margaret A., et al.
Publicado: (2012)

Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections
por: Sautto, Giuseppe, et al.
Publicado: (2013)

Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era
por: Pecetta, Simone, et al.
Publicado: (2020)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
por: Zhang, Li, et al.
Publicado: (2021)

SARS‐CoV‐2 Omicron variant: Immune escape and vaccine development
por: Ao, Danyi, et al.
Publicado: (2022)

Concentration Effects in the Interaction of Monoclonal Antibodies (mAbs) with their Immediate Environment Characterized by EPR Spectroscopy
por: Haeri, Haleh H., et al.
Publicado: (2019)

Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
por: Larrosa, Cristina, et al.
Publicado: (2023)

Endoplasmic reticulum retention motif fused to recombinant anti-cancer monoclonal antibody (mAb) CO17-1A affects mAb expression and plant stress response
por: Song, Ilchan, et al.
Publicado: (2018)

Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays
por: Passariello, Margherita, et al.
Publicado: (2023)

The Different Colors of mAbs in Solution
por: Ambrogelly, Alexandre
Publicado: (2021)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Simple Wastewater Preparation Protocol Applied to Monitor the Emergence of the Omicron 21L/BA.2 Variant by Genome Sequencing
por: Wurtz, Nathalie, et al.
Publicado: (2023)

Contrary commonwealth : the theme of exile in medieval and Renaissance Italy /
por: Starn, Randolph
Publicado: (1982)

Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study
por: Nag, Anish, et al.
Publicado: (2022)

Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus
por: Tian, Puyuan, et al.
Publicado: (2019)

Increased immune escape of the new SARS-CoV-2 variant of concern Omicron
por: Hu, Jie, et al.
Publicado: (2022)

Escape of SARS-CoV-2 Variant Omicron to Mucosal Immunity in Vaccinated Subjects
por: Martinuzzi, Emanuela, et al.
Publicado: (2022)

Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities
por: Alam, Mohammad Shah
Publicado: (2023)

VOC-DL: Deep learning prediction model for COVID-19 based on VOC virus variants
por: Liao, Zhifang, et al.
Publicado: (2022)

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

Evolving trends in mAb production processes
por: Shukla, Abhinav A., et al.
Publicado: (2017)

State of the art in anti-cancer mAbs
por: Chiavenna, S. M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_93jtg7j43upr9nrhtmgqvdmth9